Effectiveness of a Novel Liposomal Methylglyoxal–Tobramycin Formulation in Reducing Biofilm Formation and Bacterial Adhesion
<b>Background:</b> The emergence of multidrug-resistant bacteria presents a significant global health threat. Liposomal antibiotics have shown a potential to improve antibiotic delivery and efficacy. This study aimed to develop liposomes encapsulating tobramycin (TOB) and methylglyoxal (MGO) to enhance TOB activity while reducing bacterial adhesion and biofilm formation. <b>Methods:</b> Clinical isolates of <i>Pseudomonas aeruginosa</i> and <i>Klebsiella pneumoniae</i> were characterized using whole-genome sequencing. Liposomes (Lip-MGO-TOB) were formulated using Manuka honey as a surfactant and loaded with MGO and TOB. Antibacterial activity, biofilm formation, and bacterial cell adhesion assays were performed to compare the efficacy of Lip-MGO-TOB against free TOB. Liposome characterization included analyses of morphology, zeta potential, TOB encapsulation efficiency, and stability under various biological conditions. <b>Results:</b> The Lip-MGO-TOB formulation, at a minimum inhibitory concentration (MIC) of 32 µg/mL, reduced the biofilm formation of the <i>P. aeruginosa</i> isolate (PA85) by 68%. Conversely, free TOB, at a MIC of 64 µg/mL, achieved only a 21% reduction. For the <i>K. pneumoniae</i> isolate (KP57), Lip-MGO-TOB inhibited bacterial adhesion to A549 cells at a lower concentration (256 µg/mL) compared to free TOB (512 µg/mL). Lip-MGO-TOB demonstrated sustained drug release over 24 h under tested conditions and retained over 99% of TOB. <b>Conclusions:</b> The Lip-MGO-TOB formulation significantly enhanced TOB activity against resistant bacteria compared to free TOB. Additionally, it provided a stable drug delivery system with controlled drug release. Liposomal TOB represents a promising advancement in combating antibiotic resistance by improving the efficacy and delivery of conventional antibiotics.
Authors
- Alaa Eldeen B. Yassin (ORCID: https://orcid.org/0000-0003-3532-7583)
- Majed Halwani (ORCID: https://orcid.org/0000-0002-2192-3264)
- Majed F. Alghoribi (ORCID: https://orcid.org/0000-0002-2122-8640)
- Ahmed I. Al‐Asmari (ORCID: https://orcid.org/0000-0002-4488-2194)
- Raghad Alzahrani (ORCID: https://orcid.org/0000-0002-0617-7929)
- Ahmed J. Alfahad (ORCID: https://orcid.org/0000-0002-1454-6472)
- Ahlam Alsaadi (ORCID: https://orcid.org/0000-0002-7501-1180)
- Naif M. Alhawiti (ORCID: https://orcid.org/0000-0002-8357-6886)
- Rizwan Ali (ORCID: https://orcid.org/0000-0002-2475-0258)
- Manal M. Alkhulaifi (ORCID: https://orcid.org/0000-0002-5040-6303)
- Bahauddeen M. Alrfaei (ORCID: https://orcid.org/0000-0002-5740-9187)
- Wed Alluhaim (ORCID: https://orcid.org/0009-0008-7345-1028)
Institutions
- King Abdulaziz City for Science and Technology (SA)
- Alfaisal University (SA)
- King Saud bin Abdulaziz University for Health Sciences (SA)
- King Faisal Specialist Hospital & Research Centre (SA)
- King Saud University (SA)
- King Abdullah International Medical Research Center (SA)
Publication Details
- Journal
- Antibiotics
- Published
- 2024-12-24
- DOI
- https://doi.org/10.3390/antibiotics14010003
- Citations
- 3
- Primary Topic
- Antimicrobial Peptides and Activities
- Type
- article
- Field-Weighted Citation Impact
- 1.03
Funders
- King Abdullah International Medical Research Center
- King Saud bin Abdulaziz University for Health Science